scholarly journals Detection of Lymphoma in Bone Marrow by Whole-Body Positron Emission Tomography

Blood ◽  
1998 ◽  
Vol 91 (9) ◽  
pp. 3340-3346 ◽  
Author(s):  
Robert Carr ◽  
Sally F. Barrington ◽  
Bella Madan ◽  
Michael J. O'Doherty ◽  
Catherine A.B. Saunders ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Disease Status ◽  
Pet Scan ◽  
Emission Tomography ◽  
Whole Body ◽  
Whole Body Imaging ◽  
Visual Interpretation ◽  
Fdg Uptake ◽  
Positron Emission ◽  
Pet Scans

Abstract Positron emission tomography (PET) is a whole-body imaging technique using 18 fluorine-fluorodeoxyglucose (FDG), whose uptake is increased in tumor cells. Published studies have shown PET to be an effective method of staging lymphoma and to be more sensitive than CT at detecting extranodal disease. The purpose of this study was to determine whether the increased marrow uptake of FDG observed in some lymphoma patients during routine staging PET scans represented marrow involvement by disease. PET scans of 50 patients with Hodgkin's (12) and non-Hodgkin's (38) lymphoma were analyzed by three independent observers and the marrow graded as normal or abnormal using a visual grading system. Unilateral iliac crest marrow aspirates and biopsies were performed on all patients. The PET scan and marrow histology agreed in 39 patients (78%), being concordant positive in 13 and concordant negative in 26 patients. In 8 patients the PET scan showed increased FDG uptake but staging biopsy was negative; in 4 of these 8 patients the PET scan showed a normal marrow background with focal FDG “hot spots” distant from the site biopsied. In 3 patients the marrow biopsy specimen was positive but the PET scan normal; 2 of these 3 patients had non-Hodgkin's lymphoma whose malignant cells did not take up FDG at lymph node or marrow disease sites. Therefore, there were only 5 patients (10%) in whom there was a difference between the PET scan and biopsy result which could not be fully explained. Visual interpretation of marrow FDG uptake during whole-body staging PET scans can correctly assess marrow disease status in a high proportion of lymphoma patients. PET has the potential to reduce the need for staging marrow biopsy.

scholarly journals Detection of Lymphoma in Bone Marrow by Whole-Body Positron Emission Tomography

Blood ◽  
1998 ◽  
Vol 91 (9) ◽  
pp. 3340-3346 ◽  
Author(s):  
Robert Carr ◽  
Sally F. Barrington ◽  
Bella Madan ◽  
Michael J. O'Doherty ◽  
Catherine A.B. Saunders ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Disease Status ◽  
Pet Scan ◽  
Emission Tomography ◽  
Whole Body ◽  
Whole Body Imaging ◽  
Visual Interpretation ◽  
Fdg Uptake ◽  
Positron Emission ◽  
Pet Scans

Positron emission tomography (PET) is a whole-body imaging technique using 18 fluorine-fluorodeoxyglucose (FDG), whose uptake is increased in tumor cells. Published studies have shown PET to be an effective method of staging lymphoma and to be more sensitive than CT at detecting extranodal disease. The purpose of this study was to determine whether the increased marrow uptake of FDG observed in some lymphoma patients during routine staging PET scans represented marrow involvement by disease. PET scans of 50 patients with Hodgkin's (12) and non-Hodgkin's (38) lymphoma were analyzed by three independent observers and the marrow graded as normal or abnormal using a visual grading system. Unilateral iliac crest marrow aspirates and biopsies were performed on all patients. The PET scan and marrow histology agreed in 39 patients (78%), being concordant positive in 13 and concordant negative in 26 patients. In 8 patients the PET scan showed increased FDG uptake but staging biopsy was negative; in 4 of these 8 patients the PET scan showed a normal marrow background with focal FDG “hot spots” distant from the site biopsied. In 3 patients the marrow biopsy specimen was positive but the PET scan normal; 2 of these 3 patients had non-Hodgkin's lymphoma whose malignant cells did not take up FDG at lymph node or marrow disease sites. Therefore, there were only 5 patients (10%) in whom there was a difference between the PET scan and biopsy result which could not be fully explained. Visual interpretation of marrow FDG uptake during whole-body staging PET scans can correctly assess marrow disease status in a high proportion of lymphoma patients. PET has the potential to reduce the need for staging marrow biopsy.

Role of 18- Fluoro Deoxyglucose Positron Emission Tomography in Children with Leukemia

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 5605-5605
Author(s):  
Zühre Kaya ◽  
Özgür Akdemir ◽  
Ulker Kocak ◽  
Idil Yenicesu ◽  
Turkiz Gürsel
Keyword(s):  
Positron Emission Tomography ◽  
Fdg Pet ◽  
Disease Status ◽  
Pet Scan ◽  
Emission Tomography ◽  
Pediatric Leukemia ◽  
Positron Emission ◽  
Fdg Pet Scan ◽  
Pet Scans

Abstract Introduction 18-Fluoro deoxyglucose positron emission tomography (FDG-PET) is a noninvasive imaging tool for initial staging and evaluation of treatment response in several malignancy. Role of FDG-PET scan is extensively studied for lymphoma and recently findings were incorporated into the response criteria but there is lack of data for pediatric leukemia in this field. The purpose of this study was to evaluate the role of FDG-PET for disease status, for determining the effect of therapy and predicting the prognosis of pediatric leukemia. Methods We retrospectively reviewed the results of FDG-PET in 20 leukemic children treated in our department from 2005 to 2015. Whole body PET scans were performed at initial diagnosis in only two patients (2 ALL), after the first line therapy in 3 patients (3 ALL), at relapse in 6 patients (5 lymphoma-leukemia, 1 ALL) and in 9 patients following allogeneic stem cell transplantation (Allo-SCT) (5 AML, 4 ALL) for evaluation of disease status. Maximum standardized uptake values (SUVmax) were used to assess the results of FDG-PET scan. All data were analysed by SPSS 15.0 programme. Results Twenty patients were enrolled in our study, 14 boys and 6 girls. Median age was 11 years (range 2 -17). Treatment response was evaluated with FDG-PET in consecutive 20 patients and 9 were negative PET scan. From these patients, two showed relapsed in a median of 20 months after their negative scan and one with surgically removed chloroma lesion was also negative PET scan. The other six patients were in complete remmision. The remaining 11 patients were positive PET scan, which was multifocal bone marrow (BM) lesions in 3 patients after allo-SCT, diffuse BM involvement in 2 patients at diagnosis and either multifocal different area (spleen, kidney, BM) or diffuse BM lesions in 6 patients at relapse. SUVmax value was significantly higher in patients with multifocal lesions (8.6±3.2) than those of patients with diffuse involvement (3.4±0.9) (p<0.05). However, only three cases showed discordant results on FDG-PET and BM biopsy following allo-SCT. These three cases with negative BM biopsy had multifocal BM lesions in PET scan simultaneously but later developed BM relapse in a median of 2 months after positive scan. Their PET scans after salvage chemotherapy were negative. Event free survival of the PET negative groups (55.6%) were insignificantly better than those of PET positive groups (18.2%) (p>0.05). Conclusions To our knowledge, there are no previous studies associated with FDG-PET values in children with leukemia. Although our results should be confirmed in a prospective study in a large number of patients, we believe that FDG-PET value may guide physicians to show multifocal BM lesions for possible early relapse, even if BM examination indicate normal and thus it may also be helpful to identify high risk leukemic patients who need a more intensive treatment approach. Disclosures No relevant conflicts of interest to declare.

Incidence of Thyroid Carcinoma in Fluorodeoxyglucose Positron Emission Tomography-Positive Thyroid Incidentalomas

2007 ◽  
Vol 137 (3) ◽  
pp. 400-404 ◽  
Author(s):  
Deanne L. King ◽  
Brendan C. Stack ◽  
Paul M. Spring ◽  
Ronald Walker ◽  
Donald L. Bodenner
Keyword(s):  
Positron Emission Tomography ◽  
Medical Center ◽  
Tertiary Care ◽  
Needle Aspiration ◽  
Emission Tomography ◽  
Whole Body ◽  
Malignancy Rate ◽  
Positron Emission ◽  
Benign Pathology ◽  
Pet Scans

OBJECTIVE: Fluorodeoxyglucose (FDG) whole body positron emission tomography (PET) scan may show clinically occult second lesions. Such lesions in the thyroid are increasingly common. There are several recent reports of a high probability of malignancy in these lesions ranging from 14% to 63%. STUDY DESIGN AND SETTING: This is a retrospective review of 15,711 PET scans at a multi-disciplinary thyroid clinic at a tertiary care university medical center. Twenty-two patients were referred with thyroid PET “incidentalomas.” The review included 18 FDG-PET scans, ultrasound guided fine needle aspiration biopsies, and thyroid surgery pathology. Aspiration cytology or pathology were the main outcome measures. RESULTS: Three patients had malignancy of the PET-positive thyroid lesions. Papillary thyroid micro carcinomas were detected in four of the specimens that showed a benign pathology of the dominant nodule. CONCLUSION: Our experience shows a 14% malignancy rate for the dominant (imaged) nodule and a total malignancy rate of 32% when the incidental micro carcinomas are included. Both of these rates are significantly lower than results published previously.

Prognostic Value of Positron Emission Tomography (PET) Scan in Patients with Relapsed Hodgkin Lymphoma or Aggressive Non-Hodgkin Lymphoma Receiving Salvage Chemotherapy Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 3039-3039 ◽  
Author(s):  
Anna Dodero ◽  
Roberto Crocchiolo ◽  
Francesca Patriarca ◽  
Fabio Ciceri ◽  
Nicolo’ Frungillo ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Hodgkin Lymphoma ◽  
Prognostic Value ◽  
Pet Scan ◽  
Emission Tomography ◽  
Non Hodgkin Lymphoma ◽  
Positron Emission ◽  
18F Fdg ◽  
Pet Scans ◽  
Reduced Intensity

Abstract Positron emission tomography (PET) scan using 18-fluorodeoxyglucose [18F-FDG] has a prognostic value in patients (pts) with Hodgkin Lymphoma (HL) or aggressive Non-Hodgkin lymphoma (NHL) receiving chemotherapy. Chemosensitive disease is a critical prognostic factor for the success of both autologous and allogeneic stem cell transplantation (allo-SCT). We have recently shown a lower risk of death or progression for pts in CR versus those in PR before reduced-intensity conditioning (RIC) allo-SCT (Corradini P, Leukemia 2007). Thus, to better assess the value of pre-transplant disease response, we retrospectively assessed the prognostic role of PET scan before allotransplant. Between 2000 and 2007, 64 consecutive patients with a histologically proven diagnosis of aggressive NHL [n=30: diffuse large B cell lymphoma (n=18), peripheral T-cell lymphomas (n=11), Burkitt lymphoma (n=1)] or HL [n=34], responding to salvage therapy, were evaluated with a PET scan before and after allo-SCT. PET scans were performed at 3 different Nuclear Medicine Units. Presence (PET-positive) or absence (PET-negative) of abnormal 18F-FDG uptake was correlated to progression-free survival (PFS) and overall survival (OS) curves. Patients’ median age was 37 years (range, 17–65 years). Thirty-three pts (52%) were allografted from a HLA-identical sibling donor, 14 from a haploidentical donor and 17 from an unrelated donor. Pts had relapsed disease: 52 pts (81%) had failed autologous SCT, the median number of prior chemotherapy regimens was 3 (range, 1–6). All pts received a RIC regimen followed by allo-SCT. PET scans were performed at a median of 30 days prior to allograft (range, 3–90 days): 34 out of 64 pts showed an abnormal 18F-FDG uptake [NHL (n=16), HL (n=18)] whereas 30 were completely negative [NHL (n=14), HL (n=16)]. Patients with PET-positive or PET-negative scans were balanced in terms of diagnosis, previous treatments, and type of donor. At a median follow-up of 24 months (range, 6–86 months), 41 pts are alive and 23 died [toxicity n=10 (n= 5 NHL, n=5 HL), disease n=13 (n=8 NHL, n=5 HL)]. Overall, the estimated 3-year PFS in pts with negative or positive PET scans were 64% (95% CI, 42%–86%) versus 28% (95% CI, 8%–48%), respectively (p<0.005). A statistically significant higher cumulative risk of relapse was observed in pts with a positive PET scan before allografting as compared to the PET negatives (53% versus 21%, p< 0.022). The estimated 3-year OS in pts with negative or positive PET scans were 69% (95% CI; 51%–87%) versus 44% (95% CI;23%-65%), respectively (p=0.05). For NHL pts, the estimated 3-year PFS was 59% for PET-negative as compared to 38% for PET-positive (p<0.04). For HL pts, the estimated 3-year PFS was 70% for PET-negative as compared to 23% for PET-positive (p<0.05). PET scan has a clinical relevance before allo-SCT. Pts with a positive PET scan have a worse outcome, and should receive experimental therapies to target chemoresistant tumor cells.

Positron Emission Tomography Scans in the Evaluation of Postchemotherapy Residual Masses in Patients With Seminoma

1999 ◽  
Vol 17 (11) ◽  
pp. 3457-3460 ◽  
Author(s):  
Kristen N. Ganjoo ◽  
Rebecca J. Chan ◽  
Matt Sharma ◽  
Lawrence H. Einhorn
Keyword(s):  
Positron Emission Tomography ◽  
Residual Disease ◽  
Pet Scan ◽  
Emission Tomography ◽  
Positron Emission ◽  
Group A ◽  
Residual Masses ◽  
Group B ◽  
Pet Scans

PURPOSE: To assess the ability of positron emission tomography (PET) scans in differentiating between necrosis and viable seminoma in postchemotherapy (PC) residual disease. PATIENTS AND METHODS: We conducted a prospective study of 29 patients with seminoma at Indiana University. All patients had PC residual disease. Computed tomography and PET scans were performed for 19 patients after primary chemotherapy (group A) and for 10 patients after salvage chemotherapy (group B). RESULTS: In group A, the PC masses were ≥ 3 cm in 14 patients, less than 3 cm in three patients, and not quantified in two patients. All of the patients in group A had negative PET scan results and have had stable or decreasing residual mass size (median follow-up duration, 11.5 months; range, 6 to 26 months). In group B, the PC masses were ≥ 3 cm in four patients, less than 3 cm in five patients, and not quantified in one patient. One patient had a positive PET scan result for a posterior mediastinal mass. Pathologic diagnosis of the PET-positive mass showed only necrotic tissue. The same patient had a negative PET scan of the retroperitoneal mass but relapsed in that area. Overall, of patients in group B, five have stable or decreasing mass (median follow-up duration, 8 months; range, 7 to 22 months), and five had relapsed disease. CONCLUSION: PET scans have no apparent benefit in PC evaluation of residual masses in bulky seminoma.

scholarly journals Extremely low 18F-fluorodeoxyglucose uptake in the brain of a patient with metastatic neuroblastoma and its recovery after chemotherapy: A case report

2021 ◽  
Vol 10 (7) ◽  
pp. 205846012110268
Author(s):  
Yutaka Hoshino ◽  
Minako Sugiyama ◽  
Kenji Hirata ◽  
Shohei Honda ◽  
Hitoshi Saito ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Central Nervous System ◽  
Nervous System ◽  
Case Report ◽  
Emission Tomography ◽  
Whole Body ◽  
Fdg Uptake ◽  
Positron Emission ◽  
The Brain ◽  
Abnormal Uptake

Commonly, physiological 18F-fluorodeoxyglucose (FDG) uptake in the brain can be observed in 18F-FDG positron emission tomography. Abnormal uptake of 18F-FDG in the brain suggests disorders of central nervous system. Here, we present a case of extremely low 18F-FDG uptake in the brain of a 4-year-old girl with whole-body metastatic neuroblastoma. Almost missing of physiological 18F-FDG uptake in the brain was ascribed at least partly to the metastatic neuroblastoma. The brain could regain physiological 18F-FDG uptake after chemotherapy.

Voltage-gated potassium channel antibody limbic encephalitis: a case illustrating the neuropsychiatric and PET/CT features with clinical and imaging follow-up

2016 ◽  
Vol 24 (6) ◽  
pp. 538-540 ◽  
Author(s):  
Liesl Celliers ◽  
Te-jui Hung ◽  
Zeyad Al-ogaili ◽  
Girolamo Moschilla ◽  
Wally Knezevic
Keyword(s):  
Positron Emission Tomography ◽  
Potassium Channel ◽  
Limbic Encephalitis ◽  
Neuropsychiatric Symptoms ◽  
Cognitive Testing ◽  
Emission Tomography ◽  
Whole Body ◽  
Whole Body Imaging ◽  
Voltage Gated ◽  
Positron Emission

Objective: To illustrate the neuropsychiatric and imaging findings in a confirmed case of voltage-gated potassium channel antibody limbic encephalitis. Method: Case report and review of the literature. Results: A 64-year-old man presented with several months’ history of obsessive thoughts and compulsions associated with faciobrachial dystonic seizures. He had no significant past medical and psychiatric history. Physical examinations revealed only mildly increased tone in the left upper limb. Bedside cognitive testing was normal. Positron-emission tomography showed intense symmetrical uptake in the corpus striatum. No underlying malignancy was identified on whole body imaging. Magnetic resonance imaging, lumbar puncture and electroencephalogram were normal. Serum voltage-gated potassium channel antibodies were strongly positive. The patient had a favourable response to antiepileptic drugs, oral steroids and immunotherapy. Conclusions: Voltage-gated potassium channel limbic encephalitis characteristically presents with neuropsychiatric symptoms and temporal lobe seizures. Positron-emission tomography–computed tomography can be a useful adjunct to the clinical and biochemical work-up.

Sign in / Sign up

Export Citation Format

Share Document